{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:58:25Z","timestamp":1789883905674,"version":"4.0.1"},"reference-count":6,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2002,1,1]],"date-time":"2002-01-01T00:00:00Z","timestamp":1009843200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2002]]},"abstract":"<jats:p>&lt;i&gt;Background:&lt;\/i&gt; Calcipotriol is an established topical therapy for psoriasis vulgaris. &lt;i&gt;Objective:&lt;\/i&gt; This study aimed to investigate whether the addition of calcipotriol to fumaric acid ester (FAE) monotherapy had an additive efficacy and an FAE-sparing effect in patients with severe plaque psoriasis. &lt;i&gt;Methods:&lt;\/i&gt; This multicentre, randomised, double-blind, vehicle-controlled study included 143 patients for up to 13 weeks treatment. Group A received FAE tablets (Fumaderm&lt;sup&gt;\u00ae&lt;\/sup&gt;) with an increasing daily dosage from 105 to 1,075 mg + ointment vehicle. Group B received FAE tablets + calcipotriol ointment (50 \u00b5g\/g). Ointments were applied twice daily. Clinical response was assessed using percentage changes in the Psoriasis Area and Severity Index (PASI), from baseline to treatment end. &lt;i&gt;Results:&lt;\/i&gt; The mean percentage change in the PASI was \u201376.1% in group B and \u201351.9% in group A, the difference between treatments was \u201324.2% (95% CI from \u201334.2 to \u201314.2%; p &lt; 0.001). Group B responded more rapidly to treatment. Investigators\u2019 and patients\u2019 overall efficacy assessments were significantly more favourable for group B (p \u2264 0.001). Group B was prescribed less FAE than group A. This difference was greatest at the last visit (mean daily dose 529 and 685 mg, respectively; p = 0.006). Overall adverse events in the two groups were similar. &lt;i&gt;Conclusion:&lt;\/i&gt; This study shows that the combination of calcipotriol and FAEs is significantly more effective and faster acting than FAE monotherapy in the treatment of severe plaque psoriasis. The combination has a slight FEA-sparing effect and therefore a superior benefit\/risk ratio.<\/jats:p>","DOI":"10.1159\/000063148","type":"journal-article","created":{"date-parts":[[2003,4,15]],"date-time":"2003-04-15T21:05:17Z","timestamp":1050440717000},"page":"46-53","source":"Crossref","is-referenced-by-count":57,"title":["Topical Calcipotriol plus Oral Fumaric Acid Is More Effective and Faster Acting than Oral Fumaric Acid Monotherapy in the Treatment of Severe Chronic Plaque Psoriasis vulgaris"],"prefix":"10.1159","volume":"205","author":[{"given":"H.","family":"Gollnick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Altmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Christophers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2002,7,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00158.x"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/84293"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92157-W"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1159\/000018151"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(88)90177-3"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.103983"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/63148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/63148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:05:31Z","timestamp":1745467531000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000063148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002]]},"references-count":6,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2002,7,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000063148","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002]]}}}